Terms: = Endocrine gland cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
155 results:
1. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study.
Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678
[TBL] [Abstract] [Full Text] [Related]
2. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of the Thyroid cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
[No Abstract] [Full Text] [Related]
4. Therapeutic inhibition of ATR in differentiated thyroid cancer.
Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
[TBL] [Abstract] [Full Text] [Related]
5. Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology.
Wang Y; Song W; Li Y; Liu Z; Zhao K; Jia L; Wang X; Jiang R; Tian Y; He X
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16837-16850. PubMed ID: 37733241
[TBL] [Abstract] [Full Text] [Related]
6. A Preoperative Nomogram for Prediction of Postoperative Hypocortisolism in Patients with Pituitary Adenomas: A Single-Center Retrospective Cohort Study.
Ali A; Cai X; Zhu J; Geng Y; Du C; Yuan F; Yang J; Tang C; Cong Z; Ma C
World Neurosurg; 2023 Nov; 179():e135-e149. PubMed ID: 37586551
[TBL] [Abstract] [Full Text] [Related]
7. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic Thyroid cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract] [Full Text] [Related]
8. Influence factors and nomogram for volume reduction rate in benign thyroid nodule after thermal ablation.
Cao S; Wang L; Wei Y; Zhao Z; Wu J; Yu M
Int J Hyperthermia; 2023; 40(1):2220562. PubMed ID: 37344375
[TBL] [Abstract] [Full Text] [Related]
9. Inflammatory myofibroblastic tumor of the thyroid gland.
Zhang Y; Liu J
Front Endocrinol (Lausanne); 2023; 14():1156117. PubMed ID: 37255972
[TBL] [Abstract] [Full Text] [Related]
10. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract] [Full Text] [Related]
11.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract] [Full Text] [Related]
12. Comparable long-term survival outcomes of endoscopic therapy versus surgical therapy for T1-2N0M0 duodenal neuroendocrine tumors.
Liu Z; Gao J; Wang P; Yin F; Zeng C; Chen Y
Surg Endosc; 2023 Jul; 37(7):5444-5452. PubMed ID: 37036503
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of alk-Signaling Overcomes STRN-alk-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
14. Pharmacological targeting of the receptor alk inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma.
Parejo-Alonso B; Royo-García A; Espiau-Romera P; Courtois S; Curiel-García Á; Zagorac S; Villaoslada I; Olive KP; Heeschen C; Sancho P
Biomed Pharmacother; 2023 Feb; 158():114162. PubMed ID: 36571997
[TBL] [Abstract] [Full Text] [Related]
15. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M; Shu Y; Chen G; Li J; Li F
Sci Rep; 2022 Nov; 12(1):20601. PubMed ID: 36446798
[TBL] [Abstract] [Full Text] [Related]
16. Guidelines on the Use of Systemic Therapy in Patients with Advanced Thyroid cancer.
Wadsley J; Beasley M; Garcez K; Hoy S; Newbold K; Boelaert K
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):57-64. PubMed ID: 36336580
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.
Vuong HG; Le HT; Le TTB; Le T; Hassell L; Kakudo K
Pathol Res Pract; 2022 Dec; 240():154180. PubMed ID: 36306725
[TBL] [Abstract] [Full Text] [Related]
18. A semiquantitative study of the optimal whole-body imaging time after
Liu S; Zuo R; Yang T; Pang H; Wang Z
Front Endocrinol (Lausanne); 2022; 13():955387. PubMed ID: 36093082
[TBL] [Abstract] [Full Text] [Related]
19. Discovery of a novel alk/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract] [Full Text] [Related]
20. Pituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis.
Graffeo CS; Yagnik KJ; Carlstrom LP; Lakomkin N; Bancos I; Davidge-Pitts C; Erickson D; Choby G; Pollock BE; Chamberlain AM; Van Gompel JJ
Mayo Clin Proc; 2022 Oct; 97(10):1861-1871. PubMed ID: 35753823
[TBL] [Abstract] [Full Text] [Related]
[Next]
